-
GVHD Prophylaxis in Intermediate-Risk AML: Mixed Results from a Multicenter Trial
At EBMT 2025, Dr. Edouard Forcade presented the results of a multicenter randomized trial comparing cyclosporine (CsA) alone versus CsA plus mycophenolate mofetil (MMF) in patients with intermediate-risk AML in…
-
ASCO GI 2025 | Prof. Ying Yuan & Prof. Kefeng Ding on BB+CAPOX in RAS-Mutant MSS mCRC
At ASCO GI 2025, Prof. Ying Yuan shared updated data from the BB+CAPOX Phase II trial, showing a median PFS of 25.3 months in liver-only RAS-mutant MSS mCRC. Prof. Kefeng Ding highlighted the potential of this combo to convert immune-cold tumors into responsive disease.
-
ASCO GI 2025 | Spotlight on SHR1701 from Peking University Cancer Hospital
At the ASCO GI 2025 Symposium in San Francisco, experts from Peking University Cancer Hospital presented new data on SHR1701, a PD-L1/TGF-βR2 fusion protein. The Phase III results showed both survival benefits and a reduction in chemotherapy-induced myelosuppression in advanced gastric and GEJ cancers.
-
Sebastian Giebel Presents at EBMT 2025: How Prior alloHCT Shapes CART19 Outcomes in B-ALL
At EBMT 2025, Professor Sebastian Giebel shared key data from a real-world, multicenter study on CART19 therapy in 345 B-ALL patients. The study highlights how prior alloHCT exposure impacts survival…
-
EBMT 2025 | Dr. maria victoria mateos manteca on MRD as a Surrogate Marker in Myeloma Outcomes
At this year’s EBMT Annual Meeting, Dr. María-Victoria Mateos (Salamanca, Spain) delivered an impactful presentation titled “MRD in Myeloma as Surrogate Marker for Outcomes.”
-
Allogeneic SCT in Follicular Lymphoma: Still a Valid Option in the Modern Therapeutic Landscape
At EBMT 2025, Yasmina Serroukh from Erasmus MC presented a benchmark study evaluating the role of allogeneic stem cell transplantation (allo-SCT) in follicular lymphoma (FL). The analysis, drawn from a…
-
Prof. Heiner Wedemeyer on the Unfinished Mission of HCV Elimination
In a recent editorial published in the Journal of Hepatology (April 2025), Prof. Heiner Wedemeyer (Hannover Medical School) a leading voice in hepatology joined Niklas Luhmann in reflecting on more…
-
Can we truly personalize leukemia-free survival prediction after allo-HCT?
At EBMT 2025, Professor Alexandros Spyridonidis delivered a compelling presentation addressing one of the most pressing challenges in hematopoietic stem cell transplantation: how to provide patients with accurate, individualized prognostic information.
Connecting Medical Expertise through Media